[ ]

Реестр препаратов-кандидатов для лечения и профилактики COVID-19

Найдено 102 препаратов-кандидатов
Международное непатентованное наименование Сарилумаб (Sarilumab)
Торговое наименование Кевзара® (REGN88, SAR153191)
Производитель, страна Sanofi-Aventis, France
Механизм действия

Sarilumab binds to both soluble and membrane-bound interleukin6 (IL-6) receptors (sIL-6R and mIL-6R) and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T-cells and B-cells, lymphocytes, monocytes, and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation.

Текущих КИ по COVID-19 10
Международное непатентованное наименование Селинексор (Selinexor; KPT-330)
Торговое наименование Xpovio
Производитель, страна Karyopharm Therapeutics, USA
Механизм действия

Selinexor is an inhibitor of chromosome region maintenance 1 (CRM1), the major export factor for proteins from the nucleus to the cytoplasm. Binding irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as growth regulatory proteins.


FDA-approved since 2019, approved to treat multiple myeloma.

Текущих КИ по COVID-19 2
Международное непатентованное наименование Силтуксимаб (Siltuximab)
Торговое наименование Sylvant
Производитель, страна Janssen Biotech, Inc., USA
Механизм действия

SYLVANT is indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Текущих КИ по COVID-19 3
Международное непатентованное наименование Талидомид (Thalidomide)
Торговое наименование Thalomid
Производитель, страна Celgene Corporation, USA
Механизм действия

Thalidomide is used as a first-line treatment in multiple myeloma in combination with dexamethasone or with melphalan and prednisone, to treat acute episodes of erythema nodosum leprosum, and for maintenance therapy. The bacterium that causes tuberculosis (TB) is related to leprosy. Thalidomide may be helpful in some cases where standard TB drugs and corticosteroids are not sufficient to resolve severe inflammation in the brain.

Текущих КИ по COVID-19 2
Международное непатентованное наименование Таниралейсел (Taniraleucel; CYNK-001)
Торговое наименование -
Производитель, страна Celularity Incorporated, USA
Механизм действия

CYNK-001 is a cell-based therapy comprised of natural killer (NK) cells derived from placental stem cells. These cells can be frozen, culture-expanded, and administered to patients. NK cells play a major role in the body getting rid of virally infected cells, including those infected with SARS-CoV-2.

Текущих КИ по COVID-19 1
Международное непатентованное наименование Тенофовир+Эмтрицитабин (Emtricitabine&Tenofovir disoproxil fumarate)
Торговое наименование Truvada, Трувада
Производитель, страна Gilead Sciences, USA
Текущих КИ по COVID-19 2
Международное непатентованное наименование Тимозин (Thymosin)
Торговое наименование -
Производитель, страна -
Механизм действия

Thymosins are a family of small proteins that are found in many animal (and human) tissues and have a wide array of functions. One such function is their ability to regulate cellular immunity in sepsis patients.

Текущих КИ по COVID-19 3
Международное непатентованное наименование Тирозил-D-аланил-глицил-фенилаланил-лейцил-аргинин (Tyrosine-D-alanyl-glycyl-phenylalanyl-leucyl-arginine diacetate)
Торговое наименование Даларгин
Производитель, страна ФГБУ "НМИЦ кардиологии" Минздрава России; НПО "Микроген", Россия; НПП "БиоВетТехнологии", Россия; Эллара, Россия; "КОМПАНИЯ "ДЕКО", Россия
Механизм действия

Даларгин подавляет протеолиз, заживляет трофические язвы и защищает органы и ткани (легких, печени, поджелудочной железы). При комплексной интенсивной терапии полиорганной недостаточности Даларгин существенно снижает тяжесть респираторного дистресс-синдрома.

Текущих КИ по COVID-19 1
Международное непатентованное наименование Тофацитиниб (Tofacitinib)
Торговое наименование Xeljanz, Jakvinus, Tofacinix
Производитель, страна Pfizer Inc., USA
Механизм действия

Tofacitinib is an inhibitor of Janus kinases (JAK). This inhibition prevents the activation of the signal transducers and activators of transcription (STAT) which may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both the inflammatory response and the inflammation-induced damage caused by certain disease such as severe COVID-19.


FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis

Текущих КИ по COVID-19 1
Международное непатентованное наименование Тоцилизумаб (Tocilizumab)
Торговое наименование Актемра®
Производитель, страна Roche Holding, Switzerland
Механизм действия

Tocilizumab inhibits IL-6-mediated signaling by competitively binding to both soluble and membrane-bound IL-6 receptors. IL-6 is a proinflammatory cytokine that is involved in diverse physiological processes such as T-cell activation, immunoglobulin secretion induction, hepatic acute-phase protein synthesis initiation, and hematopoietic precursor cell proliferation and differentiation stimulation. IL-6 is produced by various cell types, including T- and B-cells, lymphocytes, monocytes, and fibroblasts.

Текущих КИ по COVID-19 24